VMD Sciences spotlights managed access for canine cancer care
CURRENT BRIEF VERSION: VMD Sciences said it helped a U.S. veterinary oncologist import an EMA-approved tyrosine kinase inhibitor for an 8-year-old dog with metastatic mast cell cancer through its global Managed Access Program. In the January 30, 2026 announcement, the company said Dr. Seth Glasser, DVM, DipACVIM (Oncology), of Garden State Veterinary Specialists in New Jersey used the pathway after standard options had failed for the patient, Jetta, who had a low-grade subcutaneous mast cell tumor with lymph node metastasis. VMD Sciences said it handled regulatory documentation, customs clearance, and FDA inspection support to bring in a drug not otherwise available in the U.S. (static1.squarespace.com)
Why it matters: For veterinary professionals, the case highlights a practical route to access non-U.S. therapies when approved domestic options are limited. Mast cell tumors remain one of the most common canine skin malignancies, but they can also be deceptively hard to identify early because they often resemble benign skin masses. That diagnostic challenge may start to ease: IDEXX said in January 2026 that it plans to add canine mast cell tumor detection to its Cancer Dx Panel in mid-2026 and introduce in-clinic fine needle aspirate cytology for mast cell tumors on the inVue Dx Cellular Analyzer, potentially speeding workups and treatment decisions. Once treatment starts, supportive care also matters; the FDA has renewed conditional approval of crofelemer delayed-release tablets (Canalevia-CA1) for chemotherapy-induced diarrhea in dogs through December 21, 2026, preserving an indication-specific option that may help some patients stay on protocol. While U.S. clinicians already have options including Palladia and conditionally licensed specialist-only immunotherapy such as gilvetmab, this case underscores that managed access may extend the menu further in select patients, especially when a clinician has prior experience with a drug used abroad. (acvs.org; vetcandyradio.com; vetcandyradio.com)
What to watch: Whether more specialty practices begin using managed access pathways for oncology drugs, whether new diagnostic tools for mast cell tumors gain traction in general practice and referral settings, and whether regulators or industry groups move to clarify how these case-by-case imports should fit into routine cancer care. (vmdsciences.com)